Crinetics Pharmaceuticals, Inc. Submits Form 144 Filing – Get the Latest Update
Crinetics Pharmaceuticals, Inc. (0001658247) has filed Form 144 with the Securities and Exchange Commission (SEC), indicating a plan to sell restricted shares. This filing is significant as it provides insight into the intentions of major shareholders or insiders to divest their holdings. Form 144 is typically filed when these individuals plan to sell their shares in the open market, signaling a potential shift in ownership structure.
Crinetics Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s innovative approach to drug development has positioned it as a key player in the biotech industry. For more information about Crinetics Pharmaceuticals, Inc., visit their official website at https://www.crinetics.com/.
Form 144 is a notice of proposed sale of securities filed with the SEC by an individual, company, or group that owns restricted securities. This form is required when the amount of securities to be sold exceeds 5,000 shares or $50,000 in any three-month period. It serves as a disclosure document to provide transparency to investors regarding potential insider selling activities.
Read More:
Crinetics Pharmaceuticals, Inc. Submits Form 144 Filing to SEC – Find Out More About the Company
